Regeneron Pharma (REGN) Tops Q3 EPS Views; Raises FY12 EYLEA Net Sales Outlook

October 24, 2012 6:33 AM EDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q3 EPS of $1.89, $0.93 better than the analyst estimate of $0.96. Revenue for the quarter came in at $428 million versus the consensus estimate of $349.17 million.

Regeneron now sees FY12 EYLEA net product sales of $790 to $815 million

For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Hot Guidance

Related Entities